Arovella Therapeutics Limited has appointed Dr Nicole van der Weerden as their Chief Operating Officer to support the development of their iNKT cell therapy platform towards clinical trials.

Dr Nicole van der Weerden brings 15 years of strong leadership experience in the biotechnology industry, and holds a PhD in biochemistry from La Trobe University and an MBA from Melbourne Business School.

Additionally, Arovella Therapeutics is commercialising ZolpiMist, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia.

ZolpiMist is approved by the FDA and the TGA and is marketed in the USA.

Arovella has rights to the product outside of the US and Canada.